Company Profile
Repare Therapeutics Stock Price, News & Analysis
Company overview
Business overview
Repare Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Repare Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Repare Therapeutics follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Repare Therapeutics sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Why the stock is moving
RPTX is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Repare’s catalysts are synthetic-lethality oncology programs and any update that clarifies whether the company can still build a meaningful platform story. The next data step matters.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025
Source: Repare Therapeutics
- 02
Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics
Source: Repare Therapeutics
- 03
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial Results
Source: Repare Therapeutics
- 04
Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib
Source: Repare Therapeutics
- 05
Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
Source: Repare Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.